science journalist. molecular biologist. curious. Contributing Correspondent at @sciencemagazine, reporting on #covid19. Interested in all things #blue
“Because #B117 can grow exponentially even in communities that are keeping #SARSCoV2 under control, the situation is extremely urgent. If we want vaccination to win this new race, we have to slow down the new virus while it’s still rare.”
Resident Fellow @AEI. Partner @NEA. Contributor @CNBC. 23rd Commissioner @US_FDA 2017 to 2019. Boards: @Pfizer @Illumina @AetionInc @TempusLabs
A strategy for countering UK Covid variant. We must pay equal worry to SA variant. It may be a major threat. It might partially defeat some existing medical countermeasures. Is it more fit? We're not actively looking for it, or acting with proper urgency. statnews.com/2021/01/09/we-…
👇 Both variants are ones to watch. That means not relying on S-gene dropout alone to screen. And we can't stop at genomic surveillance, we also need to prepare to act. Same tools - vaccination, testing, masks, community mitigation - new urgency. twitter.com/ScottGottliebM…
With @mlipsitch: We can slow the new virus if we
1) Screen positive SARS-CoV-2 tests to find all clusters
2) Prioritize test-trace-isolate of B.1.1.7
3) Consider community vaccination around growing clusters
Probabilistic optimist | Infectious disease, decision science, policy modeling, global health | Professor @StanfordMed | Director @PrevPolicy
Great piece from @kesvelt @mlipsitch. We have a chance to get ahead of B-117 with a combination of screening among confirmed SARS-CoV2 for the variant, and prioritizing testing, tracing and vaccination where B-117 is found. But the clock is ticking.
I've worked on all of science, from B cells to T cells.
'Most important, the new vaccines that have been developed against SARSCoV2 & that are being rolled out in the US and several other countries around the world are likely to protect us against B-117, meaning vaccination campaigns could defeat both viruses'